Ziran Li

发表

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study

Zhongqi Li, Haiyong Wang, L. Teng, 2022, Journal for ImmunoTherapy of Cancer.

Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.

B. Peng, Lei Yang, Y. Bai, 2023, JAMA.